These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 31353933)

  • 1. Psychosis induced by antidepressant treatment with reboxetine.
    Naidu C; Kulkarni J
    Aust N Z J Psychiatry; 2019 Dec; 53(12):1227-1228. PubMed ID: 31353933
    [No Abstract]   [Full Text] [Related]  

  • 2. A case of transient hallucination with ropinirole augmentation antidepressant in a patient with treatment-resistant depression: Is there differential effect of ropinirole dose on developing psychotic symptom?
    Pae CU; Marks DM; Han C; Patkar AA
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 May; 32(4):1087-8. PubMed ID: 18384925
    [No Abstract]   [Full Text] [Related]  

  • 3. Resistant depression associated with lupus erythematosus and steroid therapy.
    Benazzi F
    Can J Psychiatry; 1997 Jun; 42(5):530-1. PubMed ID: 9220120
    [No Abstract]   [Full Text] [Related]  

  • 4. [Depressive syndrome, psychoses, dementia: frequent manifestations in Parkinson disease].
    Wedekind S
    MMW Fortschr Med; 2005 Jun; 147(22):11. PubMed ID: 15977623
    [No Abstract]   [Full Text] [Related]  

  • 5. Psychoses associated with bupropion treatment.
    Golden RN; James SP; Sherer MA; Rudorfer MV; Sack DA; Potter WZ
    Am J Psychiatry; 1985 Dec; 142(12):1459-62. PubMed ID: 3934991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reboxetine-induced spontaneous ejaculation.
    O'Flynn R; Michael A
    Br J Psychiatry; 2000 Dec; 177():567-8. PubMed ID: 11102344
    [No Abstract]   [Full Text] [Related]  

  • 7. An open trial of reboxetine in HIV-seropositive outpatients with major depressive disorder.
    Carvalhal AS; de Abreu PB; Spode A; Correa J; Kapczinski F
    J Clin Psychiatry; 2003 Apr; 64(4):421-4. PubMed ID: 12716244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The promises and pitfalls of reboxetine.
    Page ME
    CNS Drug Rev; 2003; 9(4):327-42. PubMed ID: 14647527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of sexual dysfunction with the selective noradrenaline reuptake inhibitor reboxetine during treatment for major depressive disorder.
    Clayton AH; Zajecka J; Ferguson JM; Filipiak-Reisner JK; Brown MT; Schwartz GE
    Int Clin Psychopharmacol; 2003 May; 18(3):151-6. PubMed ID: 12702894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antidepressants and mania.
    Healy D
    Am J Psychiatry; 1988 Jul; 145(7):906-7. PubMed ID: 3381945
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive offsodes.
    Berzewski H; Van Moffaert M; Gagiano CA
    Eur Neuropsychopharmacol; 1997 Apr; 7 Suppl 1():S37-47; discussion S71-3. PubMed ID: 9169309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reboxetine versus imipramine in the treatment of elderly patients with depressive disorders: a double-blind randomised trial.
    Katona C; Bercoff E; Chiu E; Tack P; Versiani M; Woelk H
    J Affect Disord; 1999 Oct; 55(2-3):203-13. PubMed ID: 10628889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reboxetine: a selective norepinephrine reuptake inhibitor for the treatment of depression.
    Scates AC; Doraiswamy PM
    Ann Pharmacother; 2000 Nov; 34(11):1302-12. PubMed ID: 11098346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Toxic psychosis as an acute manifestation of diphenhydramine poisoning].
    Schreiber W; Pauls AM; Krieg JC
    Dtsch Med Wochenschr; 1988 Feb; 113(5):180-3. PubMed ID: 3338401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reboxetine treatment and pseudopheochromocytoma.
    Zornitzki T; Knobler H; Schattner A
    QJM; 2007 Jan; 100(1):61-2. PubMed ID: 17175558
    [No Abstract]   [Full Text] [Related]  

  • 16. Role of serotonin and noradrenaline in social dysfunction: a review of data on reboxetine and the Social Adaptation Self-evaluation Scale (SASS).
    Keller M
    Gen Hosp Psychiatry; 2001; 23(1):15-9. PubMed ID: 11226552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New-onset psychosis and emergence of suicidal ideation with aripiprazole.
    Selvaraj V; Ramaswamy S; Sharma A; Wilson D
    Am J Psychiatry; 2010 Dec; 167(12):1535-6. PubMed ID: 21131415
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of reboxetine on Hamilton Depression Rating Scale factors from randomized, placebo-controlled trials in major depression.
    Ferguson JM; Mendels J; Schwart GE
    Int Clin Psychopharmacol; 2002 Mar; 17(2):45-51. PubMed ID: 11890185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyponatremia associated with the initiation of reboxetine therapy.
    Abdelrahman N; Kleinman Y; Rund D; Da'as N
    Eur J Clin Pharmacol; 2003 Jun; 59(2):177. PubMed ID: 12734611
    [No Abstract]   [Full Text] [Related]  

  • 20. Reboxetine: a double-blind comparison with fluoxetine in major depressive disorder.
    Massana J; Möller HJ; Burrows GD; Montenegro RM
    Int Clin Psychopharmacol; 1999 Mar; 14(2):73-80. PubMed ID: 10220121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.